Mystakidou K et al. – Oral and IV routes for ibandronic acid have similar efficacy and tolerability in bone metastases Methods
Study to directly compare the clinical response to and safety of oral vs IV ibandronic acid for metastatic bone disease in pts age >=18 yrs with breast, prostate, lung, urogenital or colon cancer
Administration of IV ibandronic acid 6 mg infused over 15 min every 28 days or oral ibandronic acid 50 mg/day
Bone scintigraphy, radiography and serum C-terminal telopeptide of type I collagen (S-CTX) at months 3–6 to determine clinical response
Review of adverse events and biochemical safety measures
Results
Complete/partial response in 84.6% ot pts to IV route and 88.5% of pts to oral route
Median percentage decreases in S-CTX were -39% and -35% for IV vs oral routes, respectively
Bone pain scores decreased and analgesic use increased from month 0–3 and were stable from months 3–6
Both oral and IV routes improved physical and functioning scores
See all
